Type 2 DM Flashcards

1
Q

What is Diabetes Mellitus?

  • meaning and
  • diagnostic terms
A
  • a condition where the blood glucose is above an internationally accepted levels
  • Usual Clinical diagnosis of blood-
    • Glucose: = or > 11.1mmol/l + symptoms
    • Glucose = or > 11.1 mmol/l x 2
    • HbA1c = or > 48mmol/mol (6.5%)
      • this is Glycohaemoglobin or glycated haemoglobin: a measure of how well-controlled haemoglobin is in the long terms (over a 3 month period). normal levels should be below 5%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Explain the Glucose Tolerance test

A
  • 75 g Glucose Tolerance test
    • Diabetes Mellitus indicated when
      • Fasting plasma glucose = / > 7 mmol/l
      • 2 hour plasma glucose = / > 11.1 mmol/l
    • Impaired Glucose Tolerance indicated when
      • 2-hour glucose between 7 -11 mmol/l
    • Impaired Fasting Glucose indicated when
      • Fasting glucose between 6 – 6.9 mmol/l
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is Type 2 Diabetes Mellitus from a physiological perspective?

A
  • insulin resistance +
  • abnormal beta-cells

which cannot produce enough insulin to keep the blood glucose normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What damages the Islet cell in T2DM?

A
  • Islet amylin polypeptide polymers secreted from pancreatic islet beta-cells and converted to amyloid deposits
    • seen as green staining in histological samples of T2DM Islet cells
  • there is a deficit in Beta-cells
  • increased beta-cell apoptosis
  • therefore less insulin is produced
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some aetiological causes of Type 2 diabetes?

A
  • Genetic
    • polygenic
    • Sox5 regulates beta-cell phenotype and is reduced in T2DM
  • Fetal Programming (epigenetic)
    • maternal hyperglycaemia
    • Intrauterine growth retardation
  • Old age
  • Change in gut microbiota
  • Glucotoxity and Lipotoxicity
    • later effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What fat is associated with T2DM?

A
  • Visceral Fat
  • Epicardial Fat
    • a strong risk for vascular disease
  • Excess fat in the pancreas
    • this is specific to T2DM & is important in preventing normal insulin production
  • Ectopic Fat
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Ectopic Fat, its effect?

A

And endocrine organ producing

  • Free fatty acids
    • causing insulin resistance
    • these are atherogenic lipids
  • Cytokines
    • causing insulin resistance
    • Inflammation
  • Procoagulant factors (PAI1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the side effects/ morbidities that accompany T2DM?

A
  • Hyperglycaemia
  • Dysregulation of lipid metabolism
  • high levels of proinflammatory cytokines
  • high levels of free radicals
  • increased susceptibility to infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the pathogenesis of retinopathies?

A

induced by the following

  • impaired autoregulation of retinal blood flow
    • maintaining constant blood flow within the relative range is impaired in hyperglycaemia
    • results in increased retinal blood flow –> shear stress in blood vessels
    • causing increased vascular leakage and the production of vasoactive substances
  • accumulation of sorbitol within the retinal cells
    • glucose – (aldose reductase)–> sorbitol
    • consumption of NADPH in the process of NADPH can result in oxidative stress
    • sorbitol accumulation –> alterations in the activity of pkC
    • Protein Kinase C may regulate vascular endothelial growth and regulate vascular permeability
  • accumulation of advanced glycosylation end products (AGEs) in the extracellular fluid
    • AGEs may cross-link with collagen and initiate microvascular complications
    • interaction between AGEs and their receptor RAGE may generate new ROS and cause vascular inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cataracts in T2DM

A
  • caused by increased generation of polyols from glucose
    • the AR pathway is the initiating factor in diabetic cataract formation
    • leads o osmotic stress in the ens –> apoptosis + increased ROS
  • 1% reduction in HBA1c reduces cataract risk by 19%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

the pathological evolution of Diabetic Nephropathy

A
  • Within the first years after the onset of diabetes
    • glomerular hyperperfusion
    • increased glomerular filtration
    • renal hypertrophy
  • Microalbuminuria (30-300mg per day) of albumin in the urine
    • predictor of progression of proteinuria –> decline of GFR
      • patients are at an increased risk of end-stage renal disease and premature CVD
  • Hyperglycemia results in increased ROS and AGEs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain the pathogenesis of diabetic neuropathy

  • Metabolic and Vascular risk factors
A

Metabolic and Vascular risk factors contribute to the pathogenesis of diabetic neuropathy

  • Metabolic risk factors
    • Advanced Glycosylation End-products (AGEs): advanced glycosylation of essential nerve proteins is implicated in this pathology
    • Sorbitol: accumulation of intracellular sorbitol –> increased cell osmolality, decreased intracellular myoinositol and Na-K-ATPase activity, and slowing in nerve conduction velocity
    • Oxidative stress__: hyperglycemia –> accumulation and stabilization of ROS which damages peripheral nerves
  • Vascular risk factors
    • potentially associated with CVD risk factors i.e increased triglyceride, increased BMI, smoking, hypertension
    • Thrombodium and tissue plasminogen activator levels are reduced in peripheral nerve microvessels from diabetic patients
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Treating/Preventing T2DM from a Lifestyle perspective

A
  • Diet
    • Eat well plate
    • Mediterranian diet
  • Excercise
    • walking the dog (manageable to patient)
  • Education
    • education programmes e.g Desmond
  • Quit smoking
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What medical treatments can be used to treat the following factors within T2DM?

  • Dyslipidaemia
  • Hypertension
A
  • Dyslipidaemia
    • statins
  • Hypertension
    • use of Aspirin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What screens for T2DM complications are there?

  • eyes
  • kidneys
  • feet
A
  • Eyes
    • Retinal Photography
    • Laser treatment when required
  • Kidneys
    • Measure urine albumin ( EMU)
    • Control Blood Pressure
    • ACE inhibitors & ARBs
  • Feet
    • Screen for neuropathy & Vascular disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clinical features need to be assessed in a diabetic foot?

A
  • Neuropathy
  • Ischemia
  • Bony deformity
  • Callus
  • Swelling
  • Skin integrity/breakdown
    • between toes and under metatarsal heads
  • Infection
  • Necrosis
17
Q

What is the effect of Insulin in Hepatic cells?

A
  • decrease gluconeogenesis
  • decrease glycogenolysis
  • decrease ketogenesis
  • increases glycogen synthesis
18
Q

What is the effect of Insulin in muscle cells?

A
  • increase GLUT-4 translocation to the membrane
    • increase in glucose uptake
  • increase in glucose oxidation
  • increase in glycogen synthesis
  • increases in amino acid uptake and protein synthesisis
  • decrease in glycogenolysis, and amino acid release
19
Q

What is the effect of Insulin in adipocytes?

A
  • increase glucose uptake
  • increase triglyceride synthesis
  • decrease lipolysis
20
Q

What are the various treatment options for T2DM?

  • what do they specifically target
A
  • Metformin and TZds
    • for Insulin resistance
  • SGLT-2 inhibitors
    • Renal glucose absorption
  • Insulin replacement
    • loss of beta-cell mass
  • Sulphonylureas | GLP-1 analogues | DDP-4 inhibitors
    • beta-cell dysfunction
  • Diet and exercise
    • treats obesity and dyslipidaemia

overall treating hyperglycaemia

21
Q

When is Sulphonylureas indicated as a treatment for T2DM?

  • examples
  • mechanism
A
  • patients who cannot tolerate metformin or ar not a candidate for it
    • if metformin alone is not controlling the glycaemia
  • shorting examples - Glipizide, Gliclazide, are preferred in elderly patients

Action

  • bind to and inhibit the ATP dependant K+ channel in pancreatic beta cells
  • causes depolarization of cell membrane
  • Ca2+ influx –> stimulation of insulin secretion
  • sensitizes B-cells to glucose, decreases lipolysis
  • decreases clearance of insulin the liver
22
Q

What are the side-effects of Sulphonylureas?

A
  • Hypoglycaemia
    • more common with long-acting sulphonylureas
      • glyburide, chlorpropamide
  • most likely to happen after
    • exercise or a missed meal
    • high drug dose,
    • malnourishment
    • alcohol abuse
    • impaired renal or cardiac function, GI disease
    • concurrent treatment with salicylates, sulphonamides, fibrates or warfarin, after leaving hospital
23
Q

What is the action of Biguanide drugs in T2DM?

(metformin)

A
  • they do not stimulate insulin release or cause hypoglycemia
  • biguanides increase glucose uptake in muscle and decrease glucose production by the liver
  • decrease hepatic liver production through AMP-activated protein kinase (AMPK) dependent and independent pathways
24
Q

Go over the mechanism of action of Biguanide drugs

A
  • Suppression of hepatic glucose production through AMPK pathways
    • AMPK increases expression of nuclear transcription factor SHP
    • inhibits the expression of hepatic gluconeogenesis genes PEPCK and G-6-P
  • Increases insulin sensitivity
    • Possibly through improved insulin binding to insulin receptors
  • Enhances peripheral glucose uptake
    • Increased GLUT 4 translocation through AMPK
    • Heart muscle metabolic changes via p38 MAPCK and PKC-dependent mechanisms and independent of AMPK
  • Increases fatty acid oxidation via decreasing insulin-induced suppression of fatty acid oxidation
  • Decreases glucose absorption from GI tract
25
What are the pharmacological properties of metformin?
* orally active * doesn't bind to plasma proteins * excreted unchanged in urine * half-life 1.3-4.5h
26
What are the indications/ uses of Metformin?
* first line treatment for T2DM unless otherwise contraindicated * dose gradually titrated until maximum effective dose reached * combined with other anti-diabetic mediation in a single drug * also used for polycystic ovary syndrome
27
What are the side-effects and contraindications of Metformin?
* GI side effects * nausea, anorexia, abdominal discomfort, diarrhoea, metallic taste in the mouth * Lactic acidosis (rare) * more frequent in a patient with renal impairment also _contraindicated in those with_ * reduced tissue perfusion, infection, * cardiac failure, chronic hypoxic lung disease * liver disease, or alcohol abuse * individuals with a past history of lactic acidosis * vit B12 and folate absorption decreased with chronic metformin an **MI** or **septicemia** mandate immediate stoppage
28
What is the mechanism of action of Thiazolidinediones?
* increases insulin sensitivity and the peripheral uptake and utilization of glucose in muscle and fat * _bind to and activate PPARs which regulate gene expression and regulation of adipocyte lipid metabolism_ * Peroxisome proliferator-activated receptor-gamma * may facilitate glucose transport in skeletal muscle * may work in regulating the expression of adipose tissue adipokines * may reduce hepatic glucose production and improve pancreatic beta-cell dysfunction
29
When are Thiazolidinediones (Glitazones) indicated?
* May be considered when sulphonylureas is contraindicated or when hypoglycaemia is particularly undesirable * used when potentially aiming to reduce HbA1c levels * *pioglitazone* may be added to metformin and/ or sulphonylureas in individuals without risk for heart failure or fracture
30
What are the pharmacokinetics of Glitazones (thiazolidinediones)?
* Pioglitazone: taken once or twice a day orally * plasma levels peak about 3hr * the plasma half-life is 3-7hr; active metabolites (16-24h) * metabolised in the liver * excreted in faeces (2/3) and urine (1/3)
31
What are the side effects of Glitazones? - drug interactions/ contraindications
* cause fluid retention causing oedema and mild anaemia * increase the risk of heart failure * dose-related weight gain * safety in pregnancy and lactation not determined * increased incidence of fractures in females treated with *rosiglitazone* * *Pioglitazone* has many drug interactions as it is metabolised in the liver * may lower levels of oral contraceptive drugs containing Ethinyl estradiol and norethindrone
32
What is the effect of Glucagon-Like peptide (GLP-1) analogues
* increase glucose-dependent insulin secretion * decrease glucagon secretion and hepatic glucose output * regulates gastric emptying and decreases the rate of nutrient absorption * decreases food intake * decreases plasma glucose acutely to near normal levels * has a short duration in plasma
33
Give an example of a GLP-1 and describe it's the mechanism of action
*Exanatide* * administered s.c. injection 30 to 60 mins before last meal of day * Facilitates glucose control by; * Augmenting pancreas response * Suppresses pancreatic release of glucagon helping stop the liver overproducing glucose * Slows down gastric emptying * Reduces appetite and promote satiety via hypothalamic receptors * Reduces liver fat content * has a longer duration in plasma than actual GLP-1
34
What are the side effects of GLP-1 analogues?
* Mainly GI problems * acid or sour stomach * belching * diarrhoea * heartburn
35
What are Dipeptidyl peptidase-4 (DPP-4) inhibitors?
* Class of oral hypoglycemic agents * Mechanism of action is via increased levels of Incretins GLP-1 and GIP * Increased Incretins * Inhibit glucagon release * Increase glucose-induced insulin secretion * Decrease gastric emptying * Reduce hepatic glucose production * Improved peripheral glucose utilisation * Drugs in this class include *vildagliptin* (reversible), *sitagliptin* (reversible) and *saxagliptin* (covalently bound)
36
What are Sodium-glucose transport (SGLT) protein inhibitors? - examples
* drugs that inhibit the reabsorption of glucose from the proximal convoluted tubule in the nephron * SGLT-2 proteins transport glucose against a concentration gradient and the inhibitors blocks this process * *Dapagliflozin* * *Canagliflozin*
37
What are the effects of SGLT2 inhibitors?
reversal of hyperglycaemia by inhibitors Na+-Glu cotransporter --\> the reversal of glucotoxicity, so these effects are seen * increases insulin sensitivity in muscle * increased GLUT4 translocation * increased insulin signalling * Increased Insulin sensitivity in the liver * decreased action of glucose-6-phosphatase * Decreased Gluconeogenesis * decreased Cori cycle * decreased PEP carboxykinase * Improved beta cell fuction
38
What are the side effects of SGLT2 Inhibitors?
* Rapid weight loss * Tiredness * Osmotic diuretic --\> dehydration * _Can worsen urinary tract infections and thrush_
39
Review the available treatments for T2DM